Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Cytori Therapeutics (NASDAQ:CYTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Biota Pharmaceuticals (NASDAQ:BOTA)

Technology Stocks News 6

Seattle Genetics, Inc (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average price of $34.86 per share, for a total transaction of $9,829,230.18. Following the transaction, the director now directly owns 76,997 shares of the company’s stock, valued at approximately $2,684,115. Seattle Genetics, Inc. (NASDAQ:SGEN) stock performance was -0.05% in last session and finished the day at $40.10. Traded volume was 741,406.00million shares in the last session and the average volume of the stock remained 1.20million shares. The beta of the stock remained 1.38. Seattle Genetics, Inc. (NASDAQ:SGEN) insider ownership is 1.40%.

Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. purchased 103,386 shares of the stock on the open market in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average price of $2.32 per share, with a total value of $239,855.52. Following the completion of the transaction, the director now directly owns 578,389 shares in the company, valued at approximately $1,341,862. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 12.66 percent to $2.58 Thursday on volume of 647,131.00million shares. The intra-day range of the stock was $2.25 to $2.68. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $260.31million.

Cytori Therapeutics Inc (NASDAQ:CYTX) Director David Rickey acquired 30,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average price of $2.34 per share, for a total transaction of $70,200.00. Following the acquisition, the director now directly owns 15,819 shares of the company’s stock, valued at approximately $37,016. Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX)’s stock on June 12, 2014 reported a decrease of -0.40% to the closing price of $2.48. Its fifty two weeks range is $2.00 -$3.93. The total market capitalization recorded $187.14million. The overall volume in the last trading session was 466,469.00million shares. In its share capital, CYTX has 79.53million outstanding shares.

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) (10% owner) REGALS CAPITAL MANAGEMENT LPRegals Fund LPSlager David Mark  purchased 2,252 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 6th. The shares were purchased at an average price of $4.44 per share, for a total transaction of $9,999.00. On Thursday, shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) advanced 2.50% to close the day at $11.05. Company monthly performance is recorded as 19.33%. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) quarterly revenue growth is -3.75%.

Biota Pharmaceuticals Inc (NASDAQ:BOTA) CEO Russell H. Plumb purchased 32,031 shares of the stock on the open market in a transaction that occurred on Wednesday, June 11th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $95,772.69. Following the acquisition, the chief executive officer now directly owns 127,579 shares of the company’s stock, valued at approximately $381,461. Biota Pharmaceuticals Inc (NASDAQ:BOTA) stock performance was -0.65% in last session and finished the day at $3.05. Traded volume was 104,572.00million shares in the last session and the average volume of the stock remained 180.24K shares. The beta of the stock remained 1.42. Biota Pharmaceuticals Inc (NASDAQ:BOTA) insider ownership is 15.42%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone